Nagy Habib
Imperial College London
UK
Biography
Nagy Habib is Lead Clinician for the Liver and Pancreatic Unit at Imperial College Healthcare NHS Trust and Academic Head of the Department of Surgery at the Hammersmith Hospital Campus of Imperial College London. Habib is a translational researcher who pioneered the first clinical trial in the use of plasmid and adenovirus for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He was also the Principal Investigator of the world first clinical trials published on the use of adult bone marrow-derived stem cells for the treatment of patients with liver insufficiency and CD34+ cells in patients with stroke. As a clinical scientist he has conducted and published translational research in liver tumours on oncogene, tumour suppressor gene, epigenetic modification, gene therapy, stem cell therapy, and small activating RNA. He was the inventor and was co-author on the first publication to describe the use of radiofrequency energy in devices for liver surgery (Habib 4X), interventional endoscopy (Habib™ EndoHPB and Habib™ EUS-RFA) and interventional radiology (Habib™ VesOpen). He holds a gold award from the Advisory Committee for Clinical Excellence which is given to recognise and reward the exceptional contribution of NHS consultants, over and above that normally expected in a job, to the values and goals of the NHS and to patient care, and he was named as one of Britain’s top surgeons in December 2011 by the Saturday Times Magazine. He was awarded Honorary Professorships by universities in China, Bulgaria, Greece, and Russia. In November 2012 he was awarded Takreem Laureate for his contribution to technology and science.
Abstract
Abstract : Preclinical and clinical results of a subset of CD34+ cells
Speaker Presentations